Muismonoklonale antilichamen tegen Ipilimumab (kloon: 26B6H7D9)

Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells Anti-Ipilimumab Antibody (26B6H7D9), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ipilimumab.

Ipilimumab

26B6H7D9

ELISA

Protein A chromatography

Purified

0.5 mg/mL, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.

The antibody is stable in lyophilized form if stored at -20°C or below. The reconstituted antibody can be stored for 2-3 weeks at 2-8°C. For long term storage, aliquot and store at -20°C or below. Avoid repeated freezing and thawing cycles.

ELISA detection: 0.01-0.1 μg/mL

Mouse IgG1